Myeloma and bone disease: " The dangerous tango"

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 4, 2006, Pages 300-306

  Epstein, Joshua ^a   Walker, Ronald ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Department of Radiology ^*

Author keywords

Imaging; Lytic bone disease; Myeloma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; GLUCOCORTICOID; PAMIDRONIC ACID; PREDNISONE; PROTEASOME INHIBITOR;

ARTICLE; BODY BUILD; BONE DISEASE; BONE MARROW CELL; BONE METASTASIS; BONE PAIN; CANCER GROWTH; COMPRESSION FRACTURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG MEGADOSE; FUNCTIONAL ASSESSMENT; HUMAN; INTRAMEDULLARY NAILING; KYPHOPLASTY; LONG TERM CARE; MYELOMA; MYELOMA CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PERCUTANEOUS VERTEBROPLASTY; POSITRON EMISSION TOMOGRAPHY; VERTEBRA FRACTURE;

BONE NEOPLASMS; FRACTURES, BONE; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS;

EID: 33745219872     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Klein-Nulend J, Nijweide PJ, Burger EH. Osteocyte and bone structure. Curr Osteoporos Rep. 2003;1:5-10.
2. Suva LJ, Gaddy D, Perrien DS, Thomas RL, Findlay DM. Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep. 2005;3:46-51.
3. Plotkin LI, Mathov I, Aguirre JI, Parfitt AM, Manolagas SC, Bellido T. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol. 2005;289:C633-C643.
4. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005;11:76-81.
5. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med. 2000;108:153-164.
6. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439-446.
7. O'brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835-1841.
8. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907-2912.
9. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
10. Bataille R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol. 1990;76:484-487.
11. Rogers JS, Spahr J, Judge DM, Varano LA, Eyster ME. IgE myeloma with osteoblastic lesions. Blood. 1977;49:295-299.
12. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
13. Kyle RA. Monoclonal gammopathy of undetermined significance (MGUS). Baillieres Clinical Haematology. 1995;8:761-781.
14. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoblasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62-66.
15. Dhodapkar MV, Weinstein R, Tricot G, et al. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma. 1998;32(1-2):121-127.
16. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lyric bone disease. J Clin Oncol 1989;7:1909-1914.
17. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-ihibitory faccrot and is identical to trance/rankl. Pro Nat Acad Sci U S A. 1998;95:3597-3602.
18. Li J, Sarosi I, Yan XQ, Morony S, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97:1566-1571.
19. Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999;27:1229-1241.
20. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974;291:1041-1046.
21. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-11586.
22. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma. 2003;44:1463-1467.
23. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002;100:3002-3007.
24. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 2003;63:5438-5445.
25. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003;9:1436-1440.
26. Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, Sentry JW, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol. 2004;126:192-201.
27. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290.
28. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195-2202.
29. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97:3349-3353.
30. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004;125:38-41.
31. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003;123:106-109.
32. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-319.
33. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739-750.
34. Mbalaviele G, Sheikh S, Stains JP, Salazar VS, Cheng SL, Chen D et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005;94:403-418.
35. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
36. Gregory CA, Gunn WG, Reyes E, et al. How wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann N Y Acad Sci. 2005;1049:97-106.
37. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005.
38. Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005;106:1407-1414.
39. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol. 2003;120:235-242.
40. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica. 2004;89:567-577.
41. Corso A, Arcaini L, Mangiacavalli S, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica. 2001;86:394-398.
42. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66:337-341.
43. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000;88(12 suppl):2952-2960.
44. Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69:37-42.
45. Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta. 1996;253(1-2):61-77:32.
46. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
47. Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med. 1985;145:1451-1452.
48. Mahnken AH, Wildberger JE, Gehbauer G, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol. 2002; 178(6):1429-1436.
49. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
50. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group [see comments]. N Engl J Med. 1996;334:488-493.
51. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374.
52. Martin A, Garcia-Sanz R, Hernandez J, et al. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol. 2002;118:239-242.
53. Body JJ, Greipp P, Coleman RE, et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97(3 suppl):887-892.
54. De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol. 2004;4:340-346.
55. Cotten A, Dewatre F, Cortet B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Radiology. 1996;200:525-530.
56. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003;98(1 suppl):21-30.
57. Hentschel SJ, Burton AW, Fourney DR, Rhines LD, Mendel E. Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications. J Neurosurg Spine. 2005;2:436-440.
58. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257-259.
59. Salmon SE, Shadduck RK, Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179-187.
60. Dujovne CA, Azarnoff DL. Clinical complications of corticosteroid therapy: a selected review. Med Clin North Am. 1973;57:1331-1342.
61. Rogge CW. Necrosis of the femoral head occurring in association with corticosteroid medication. Arch Chir Neerl. 1972;24:151-163.
62. Quaade F. Undesirable effects of glucocorticoids. Acta Med Scand Suppl. 1969;500:77-80.
63. Ansell BM. Problems of corticosteroid therapy in the young. Proc R Soc Med. 1968;61:281-282.
64. Birkenhager JC, van der Heul RO, Smeenk D, van dS, V, van Seters AP. Bone changes associated with glucocorticoid excess. Proc R Soc Med. 1967;60(11 part 1):1134-1136.
65. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048.
66. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma. Cancer Res. 2003;63:287-289.
67. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003;18:482-492.
68. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64:2016-2023.
69. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484-2491.
70. Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998;103:530-532.
71. Gordon S, Helfrich MH, Sati HI, et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol. 2002;119:475-483.
72. Yaccoby S, Wezeman MJ, Henderson A, Barlogie B, Epstein J. Role and fate of osteoblasts in myleoma. Haematologica. 2006;91:192-199.
73. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003;111:1771-1782.
74. Murray EJ, Bentley GV, Grisanti MS, Murray SS. The ubiquitin-proteasome system and cellular proliferation and regulation in osteoblastic cells. Exp Cell Res. 1998;242:460-469.
75. Shimazaki C, Uchida R, Nakano S, et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoclast differentiation. Leukemia. 2005;19:1102-1103.
76. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71-73.